📊 Get daily AI-graded market briefings
Morning + evening · AI impact + sector exposure · Free
LAST 30 DAYS
7 articles
AVG GRADE
HIGH
score: 0.57
SENTIMENT
BULLISH
TOTAL VIEWS
60
ARWR Stock Analysis & AI Grade: HIGH
7 articles analyzed · Sentiment: BULLISH · AI-powered equity research
RECENT COVERAGE · 7 ARTICLES
Arrowhead Pharmaceuticals, Inc. (ARWR) Q3 2026 Earnings Call Transcript
Arrowhead Pharmaceuticals (ARWR) released its Q3 2026 earnings call transcript, providing insight into operational performance and...
5 Stocks That Created Fortunes: CMPS +327%, ARWR +222%, CGON +148%, DRTS +182%, ELMD +86%
This retrospective article highlights five small-cap equities that delivered substantial percentage gains over unspecified historical...
Arrowhead (ARWR) Soars to New High as Plozasiran Nears Expanded Commercialization
Arrowhead Pharmaceuticals (ARWR) is moving higher on progress toward expanded commercialization of Plozasiran, its investigational...
Arrowhead: Stock Up On SHTG Data - No Ceiling On Valuation Growth Potential (NASDAQ:ARWR)
Arrowhead Pharmaceuticals (ARWR) reported Phase 3 plozasiran data for severe hypertriglyceridemia (sHTG), a rare lipid disorder with...
Arrowhead Pharma Stock Jumps 24% On Positive Phase 3 Plozasiran Trial Results
ARWR experienced a substantial single-day rally following announcement of positive Phase 3 trial data for plozasiran, its...
Arrowhead Pharmaceuticals: Redemplo Meets High Expectations In SHTG Trials (NASDAQ:ARWR)
Arrowhead Pharmaceuticals (ARWR) announced Phase 3 trial success for Redemplo, demonstrating triglyceride reductions of 79-81%—a...
Parkinson's Disease Clinical Trial Pipeline Boom as 150+ Companies are in the Race for Better Treatments | DelveInsight
The Parkinson's disease therapeutic landscape is experiencing significant expansion with 150+ companies actively developing treatments...
RELATED TICKERS
E
ESEN Analytics
AI-powered equity research platform covering 5,000+ US equities. Our proprietary AI grading system (A+ to D scale) analyzes fundamentals, technicals, and news sentiment daily. Coverage data updated every 24 hours.
Learn about our methodology →
ⓘ AI-graded news coverage · Not investment advice